1. Introduction {#sec1-ijerph-16-02345}
===============

Hepatitis C is a viral infectious disease caused by the HCV, which is characterized by diffuse liver damage \[[@B1-ijerph-16-02345]\]. In 2003, the World Health Organization (WHO) estimated that the global prevalence of HCV infection was about 3.0%, with about 3--4 million new infections every year, about 130--150 million chronic infections worldwide, and about 672,000 deaths annually from acute viral hepatitis C infections and hepatitis C-related liver cancer and cirrhosis \[[@B2-ijerph-16-02345]\]. At present, the new curative treatment for HCV infection, e.g., directly acting antiviral, was available and convinced in safety, and tolerability \[[@B3-ijerph-16-02345],[@B4-ijerph-16-02345],[@B5-ijerph-16-02345]\].

However, the main route of HCV infection has changed since the early 1990s. Before the 1990s, blood transfusions and the use of contaminated blood products were the main sources of HCV infection \[[@B2-ijerph-16-02345],[@B3-ijerph-16-02345],[@B4-ijerph-16-02345],[@B5-ijerph-16-02345],[@B6-ijerph-16-02345]\]. Whereas currently, drug use is the main source of HCV infection in most developed and developing countries \[[@B2-ijerph-16-02345]\], and statistics have shown that over 50% of drug users are intravenous drug users \[[@B7-ijerph-16-02345],[@B8-ijerph-16-02345],[@B9-ijerph-16-02345]\], with an estimated 12 million injecting drug users worldwide \[[@B10-ijerph-16-02345]\]. HCV infection rates have been increasing since 2006 in some areas, especially among the younger population \[[@B9-ijerph-16-02345]\]. In addition, in the last 10 years, the number of new drug users has been increasing and there are various ways of drug use \[[@B11-ijerph-16-02345],[@B12-ijerph-16-02345],[@B13-ijerph-16-02345],[@B14-ijerph-16-02345]\]. Pan et al. also showed that the club drug users had a high prevalence of HCV infection, as well as people with high-frequency unprotected sexual behavior and less available intervention services \[[@B15-ijerph-16-02345]\]. These findings suggest that new drugs have become a new threat to human health.

In fact, in recent times, the number of global drug users has increased rapidly, from 185 million in 2004 to 250 million in 2015 \[[@B10-ijerph-16-02345],[@B16-ijerph-16-02345]\]. Similarly, the number of registered drug users in China has risen rapidly, from 70,000 in 1990 to 3 million in 2015 \[[@B17-ijerph-16-02345]\]. In view of this significant population of drug users and the risk of cross infection with HCV among drug users, the impact of HCV infection among this population remains significant and constitutes a major health burden.

In recent years, some practical measures and strategies have been implemented to tackle the spread of infections among drug users, such as publicizing health information, making condoms available in public places, providing needle/syringe exchange centers, as well as opening methadone maintenance treatment clinics that help reduce risky drug-use behaviors thereby reducing the risk of transmission of blood-borne infections \[[@B8-ijerph-16-02345],[@B18-ijerph-16-02345],[@B19-ijerph-16-02345],[@B20-ijerph-16-02345],[@B21-ijerph-16-02345],[@B22-ijerph-16-02345],[@B23-ijerph-16-02345],[@B24-ijerph-16-02345],[@B25-ijerph-16-02345]\]. However, the rates of HCV infection remain high among drug users \[[@B25-ijerph-16-02345],[@B26-ijerph-16-02345]\]. Many factors influence the development of HCV infection among drug users, such as injecting behavior, sharing needles and/or syringes, the duration of drug use, and high-risk sexual behavior \[[@B27-ijerph-16-02345],[@B28-ijerph-16-02345],[@B29-ijerph-16-02345],[@B30-ijerph-16-02345],[@B31-ijerph-16-02345],[@B32-ijerph-16-02345],[@B33-ijerph-16-02345],[@B34-ijerph-16-02345],[@B35-ijerph-16-02345]\].

In 2006, Xia et al. performed meta-analysis on data collected from drug users in China to determine factors that correlate with the occurrence of HCV infection \[[@B26-ijerph-16-02345]\], and Stone et al. performed another meta-analysis for incarceration history and risk of HCV acquisition among people who injected drugs in 2018 \[[@B36-ijerph-16-02345]\]. In another study, Hagan et al. collected data from published or released reports between January 1989 and December 2006 and data from scientific conferences between December 2006 April 2010, and meta-analyzed the effects of risk-reduction interventions \[[@B25-ijerph-16-02345]\]. They concluded that combined substance-use treatment and support for safe injection were the most effective interventions for reducing HCV seroconversion. These findings implied that appropriate intervention can prevent HCV infection among injection drug users. Studies have also demonstrated that the hazards posed by certain risk factors can be controlled. However, this meta-analysis was performed on a limited number of studies and limitations were imposed as a result of literature being unavailable. For example, in 2004, Lin et al. completed a quasi-experiment design in a controlled community intervention study that included a needle and syringe exchange program, peer education and health education, provision of free needles and syringes, and the collection of used needles, which was implemented for 10 months to injecting drug users in an intervention community, but no intervention measures were implemented in a control community for comparison \[[@B37-ijerph-16-02345]\]. A number of other studies investigating factors correlating to HCV infection in drug users have been published since 2006 \[[@B27-ijerph-16-02345],[@B28-ijerph-16-02345],[@B38-ijerph-16-02345],[@B39-ijerph-16-02345],[@B40-ijerph-16-02345],[@B41-ijerph-16-02345],[@B42-ijerph-16-02345],[@B43-ijerph-16-02345],[@B44-ijerph-16-02345],[@B45-ijerph-16-02345],[@B46-ijerph-16-02345],[@B47-ijerph-16-02345],[@B48-ijerph-16-02345],[@B49-ijerph-16-02345],[@B50-ijerph-16-02345],[@B51-ijerph-16-02345],[@B52-ijerph-16-02345],[@B53-ijerph-16-02345],[@B54-ijerph-16-02345],[@B55-ijerph-16-02345],[@B56-ijerph-16-02345],[@B57-ijerph-16-02345],[@B58-ijerph-16-02345],[@B59-ijerph-16-02345],[@B60-ijerph-16-02345],[@B61-ijerph-16-02345],[@B62-ijerph-16-02345],[@B63-ijerph-16-02345],[@B64-ijerph-16-02345],[@B65-ijerph-16-02345],[@B66-ijerph-16-02345],[@B67-ijerph-16-02345],[@B68-ijerph-16-02345],[@B69-ijerph-16-02345],[@B70-ijerph-16-02345],[@B71-ijerph-16-02345],[@B72-ijerph-16-02345],[@B73-ijerph-16-02345],[@B74-ijerph-16-02345],[@B75-ijerph-16-02345],[@B76-ijerph-16-02345],[@B77-ijerph-16-02345]\]; however, the contribution of each of the factors identified in such studies remains unclear or in some cases is even contradictory.

2. Materials and Methods {#sec2-ijerph-16-02345}
========================

2.1. Literature Search Strategy {#sec2dot1-ijerph-16-02345}
-------------------------------

Searches were performed in specified databases on the BoKu data service platform. We used the following search terms "Hepatitis C or HCV" and "drug use or drug addiction" in the search field "Title/Abstract," and searched six international databases, namely PubMed, OVID, Springer, Wiley, Elsevier, and EBSCO. We also used the search terms "Hepatitis C or "HCV" and "drug use or drug addiction" in the search field "Abstract," and searched the Chinese Medical Journal Database and Chinese National Knowledge Infrastructure. The searches were completed in the last week of March 2019.

2.2. Inclusion and Exclusion Criteria {#sec2dot2-ijerph-16-02345}
-------------------------------------

The eligibility criteria for the studies included in this meta-analysis were: (1) The study is an original research; (2) the study was an observational study with specific temporal and geographic characteristics; (3) the study was published with the full text available; (4) all cases and controls were drug users and the source of research objects was clearly stated; (5) major influencing factors were reported; and (6) hepatitis C was diagnosed by the national diagnostic criteria that existed at that time \[[@B78-ijerph-16-02345]\].

Literature was excluded from the meta-analysis when: (1) Based on the data reported, the odds ratio (OR) with 95% confidence interval (CI) could not be achieved by calculating the major influencing factors; (2) the literature duplicated the same research; (3) according to the source of the research objects, the province (state) was used as the screening repeated research object analysis unit and for studies with the same or cross research objects, only one of the studies was included and the others were excluded; and (4) according to the declaration by Ebrahim et al., the literature satisfying the number of items in the corresponding research type declaration was less than half the total number of items \[[@B79-ijerph-16-02345],[@B80-ijerph-16-02345]\].

2.3. Data Extraction {#sec2dot3-ijerph-16-02345}
--------------------

A pre-made form was used for data extraction. The literature was assessed one-by-one and the form was completed by two trained reviewers. The following data were extracted from the qualified studies: First author, year of the study, location, sample size, the number of drug users in the HCV-infected group and the non-HCV-infected group, the number of males and females or the male to female ratio, and age distribution among drug users.

Discrepancies between the assessment results acquired by the two reviewers were resolved by checking the original documents and discussing.

2.4. Sensitivity Analysis {#sec2dot4-ijerph-16-02345}
-------------------------

In this meta-analysis, the studies with the maximum weight were omitted from the subgroup analysis. The remaining studies were pooled, and the pooled OR~weight~ values with 95% CIs for each study factor were obtained. The pooled OR~weight~ values were then compared with the pooled ORs before being omitted from the study.

2.5. Statistical Analysis {#sec2dot5-ijerph-16-02345}
-------------------------

In this meta-analysis, the main indicators were the ORs with 95% CIs. Following a heterogeneity test, the fixed effects model was used to analyze factors without heterogeneity for the different studies and the random effect model was used to analyze factors with heterogeneity using the Review Manager 5.1 software. (Cochrane Collaboration, Rigshospitalet, Denmark). Heterogeneity was evaluated using Cochran's chi-square test with a significance level of α = 0.1 and using I^2^ statistics with heterogeneity accepted as I^2^ ≤ 50% \[[@B81-ijerph-16-02345]\]. In this meta-analysis, I^2^ ≤ 50% was accepted. The Egger's test was performed using the software Stata version 11.0 (Stata Corp., College Station, TX, USA), with a significance level of α = 0.05.

3. Results {#sec3-ijerph-16-02345}
==========

3.1. Literature Search {#sec3dot1-ijerph-16-02345}
----------------------

Based on the inclusive criteria and exclusive criteria, all articles were retrieved and carefully reviewed to assess the eligibility. Forty-nine eligible studies were identified after a screening of 1109. The selection of studies for the meta-analysis is shown in [Figure 1](#ijerph-16-02345-f001){ref-type="fig"} \[[@B82-ijerph-16-02345]\].

3.2. Characteristics of the Studies {#sec3dot2-ijerph-16-02345}
-----------------------------------

Among the forty-nine studies, the 10 study factors used to pool ORs with 95% CIs were as follows: Injecting drug use (43 studies, 53,860 cases, 69,747 controls); sharing needles and syringes (33 studies, 40,777 cases, 23,361 controls); duration of drug use \>5 years (12 studies, 10,282 cases, 8,794 controls); unemployment (6 studies, 8,361 cases, 5,420 controls); sex (male) (39 studies, 57,403 cases, 72,922 controls); education level ≤9 years (29 studies, 46,931 cases, 61,841 controls); sexual behavior without a condom (15 studies, 10,032 cases, 24,156 controls); Han ethnic group (15 studies, 12,014 cases, 16,129 controls); married or cohabiting with a regular partner (26 studies, 46,626 cases, 62,107 controls); commercial sexual behavior (14 studies, 9,698 cases, 28,505 controls). Among the forty-nine studies, the proportion of 4 studies (injecting only) was 8.16%, the proportion of 2 studies (non-injecting) was 4.08%, and the proportion of 43 studies (injecting and non-injecting) was 87.76%.

The characteristics of all studies evaluated in this meta-analysis are shown in [Table 1](#ijerph-16-02345-t001){ref-type="table"}.

3.3. Results of Pooled ORs {#sec3dot3-ijerph-16-02345}
--------------------------

In this meta-analysis, the pooled ORs with 95% CIs for study factors were as follows: Injecting drug use 10.11 (8.54, 11.97); sharing needles and syringes 2.24 (1.78, 2.83); duration of drug use \>5 years 2.39 (1.54, 3.71); unemployment 1.50 (1.22, 1.85); commercial sexual behavior 1.00 (0.73, 1.38); sex (male) 1.04 (0.91, 1.18); married or cohabiting with a regular partner 0.88 (0.79, 0.98); Han ethnic group 0.94 (0.73, 1.20); sexual behavior without a condom 1.72 (1.07, 2.78); and education level ≤9 years 1.05 (0.92, 1.21).

The pooled ORs with their 95% CIs for study factors are detailed in [Figure 2](#ijerph-16-02345-f002){ref-type="fig"}, [Figure 3](#ijerph-16-02345-f003){ref-type="fig"} and [Figure 4](#ijerph-16-02345-f004){ref-type="fig"}, and the axes of the figures mean OR = 1.

3.4. Results of Heterogeneity Evaluation {#sec3dot4-ijerph-16-02345}
----------------------------------------

A heterogeneity test showed that variations among studies for the pooled ORs with 95% CIs for factors including injecting drug use, sharing needles and syringes, drug use duration of \>5 years, unemployment, commercial sexual behavior, sex (male), married or cohabiting with a regular partner, Han ethnic group, sexual behavior without a condom, and an education level of ≤9 years were statistically significant (*p* \< 0.10). The effects of these factors were then pooled using the random effect model. These results are detailed in [Figure 2](#ijerph-16-02345-f002){ref-type="fig"}, [Figure 3](#ijerph-16-02345-f003){ref-type="fig"} and [Figure 4](#ijerph-16-02345-f004){ref-type="fig"}.

3.5. Publication Bias {#sec3dot5-ijerph-16-02345}
---------------------

In this meta-analysis, a funnel plot for the duration of drug use was symmetrical, with the axis of symmetry (OR = 1) being to the right of center, as detailed in [Figure 5](#ijerph-16-02345-f005){ref-type="fig"}. The results of Egger's test for study factors were all *p* \> 0.05, as detailed in [Table 2](#ijerph-16-02345-t002){ref-type="table"}.

3.6. Sensitivity Analysis {#sec3dot6-ijerph-16-02345}
-------------------------

In view of the reliability of the pooled ORs using the random effect model for terms including injecting drug use, drug use duration of \>5 years, unemployment, commercial sexual behavior, sex (male), married or cohabiting with a regular partner, Han ethnic group, sharing needles and syringes, sexual behavior without a condom, and an education level of ≤9 years, we omitted studies with the highest weights, pooled the remaining studies, and acquired the OR~weight~ values with 95% CIs. These pooled values were compared with those obtained before the studies were omitted for qualitative and quantitative comparisons and no major changes in the pooled ORs with 95% CIs were observed for any of the study factors, as detailed in [Table 2](#ijerph-16-02345-t002){ref-type="table"}.

4. Discussion {#sec4-ijerph-16-02345}
=============

This study found that drug users with a history of injecting drug use, and/or sharing needles/syringes, drug use duration of \>5 years, and/or unemployment, and/or sexual behavior without a condom, were at increased risk of HCV infection, whereas drug users who were married or cohabiting with a regular partner were at decreased risk of developing HCV infection. This study also found that, for drug users (male), commercial sexual behavior, Han ethnicity, an education level of ≤9 years, did not affect the risk of developing HCV infection.

In general, exposure to HCV-contaminated needles and syringes increases the risk of HCV infection, and such exposure may be common among injecting drug users \[[@B83-ijerph-16-02345],[@B84-ijerph-16-02345]\]. The findings of our meta-analysis confirmed that drug users with histories of injecting drug use were at increased risk of HCV infection, and this result was consistent with those of Xia et al. \[[@B26-ijerph-16-02345]\]. However, the findings of this meta-analysis that injecting drug users with a history of sharing needles/syringes were at increased risk of developing HCV infection was not consistent with the results reported in the meta-analysis by Xia et al. in 2008, and this may be related to the fact that only three studies on sharing needles were pooled in Xia et al.'s study and that this small sample size led to low test efficiency and unreliable results \[[@B26-ijerph-16-02345]\].

The findings of this meta-analysis also showed that drug use duration of \>5 years was a risk factor for developing HCV infection, which may relate to the longer the duration of drug use, the greater the opportunity to be exposed to HCV-contaminated needles or goods, potentially leading to an infection. This result was consistent with the findings of a previous meta-analysis report \[[@B26-ijerph-16-02345]\].

In view of that, methadone maintenance treatment can reduce or put an end to risky drug-use behaviors. This discovery suggests methadone maintenance treatment should be scaled up further so as to shorten the duration of drug use and reduce the risk of HCV infections \[[@B24-ijerph-16-02345]\].

The findings of this meta-analysis also showed that sexual behavior without a condom was a risk factor for developing HCV infection. The results of the meta-analysis by Xia et al. in 2008′s meta-analysis reported that high-risk sexual practices were strongly associated with injecting drug behavior \[[@B26-ijerph-16-02345]\], but the magnitude of high-risk sexual behavior or the correlation between high-risk sexual behavior and drug-injecting behavior and their contribution to the occurrence of HCV infection could not be determined, thus requiring further study. In our study, there was a high proportion of injecting drug behavior and high-risk sexual behavior among the drug users, but related information on individual cases was not available.

The use of amphetamine-type stimulants is currently on the rise, as is unprotected sexual behavior becoming more common and leads to a high prevalence of HCV infection among the club drug user \[[@B17-ijerph-16-02345],[@B85-ijerph-16-02345],[@B86-ijerph-16-02345],[@B87-ijerph-16-02345]\], strategies therefore need to be implemented to try to reduce such behaviors and to help to reduce the progression of HCV infection. In addition, further meta-analyses for club drug use will be done when there is enough literature.

The findings of this meta-analysis also showed that unemployment among drug users increased the risk of developing HCV infection, and this finding was consistent with the results of meta-analysis of human immunodeficiency virus (HIV) infection, which has a similar transmission route, among drug users \[[@B88-ijerph-16-02345]\].

The findings of our meta-analysis showed that drug users who were married or cohabiting with a regular partner were at decreased risk of developing HCV infection, and this finding was consistent with the results of meta-analysis published by Hagan et al. \[[@B27-ijerph-16-02345]\], and this may be related to the fact that these drug users had fewer sexual partners and fewer opportunities to be exposed to HCV-infected bodily fluids. However, the findings of this meta-analysis also showed that drug users with commercial sexual behavior, namely having multiple sexual partners, were not at increased risk of developing HCV infection, and this may be related to using club drug use with a shorter duration of drug use \[[@B15-ijerph-16-02345]\], although this requires further investigation.

The findings of this meta-analysis also showed that those of Han ethnicity, compared with those of other minority ethnic groups, were not at increased or decreased risk of developing HCV infection, and this finding was consistent with the results of meta-analysis published by Xia et al. \[[@B26-ijerph-16-02345]\]. Our findings also showed that drug users with an education level of ≤9 years were not at increased or decreased risk of developing HCV infection; however, this finding was inconsistent with that of a previous meta-analysis of HIV infection, which has a similar transmission route among drug users \[[@B88-ijerph-16-02345]\].

The limitations of this study were that even though the ORs of the study factors were pooled using a random--effect method, heterogeneity among studies might have influenced the findings. In addition, some study factors, for example, some racial classifications (white or black) were not available to be pooled. Lastly, few studies could be unavailable because of language limitations, in view of that, this meta-analysis' publication bias was not statistically significant, and thus, this aspect influenced findings slightly.

5. Conclusions {#sec5-ijerph-16-02345}
==============

This study found that drug users with histories of injecting drug use, sharing needles and syringes, drug use duration of \>5 years, and unemployment, were confirmed to be at increased risk of HCV infection. Our findings indicate that high-risk drug users should be closely monitored and sterile needles and syringes should be made available to ensure safe injection. In view of that, methadone maintenance treatment can reduce or put an end to risky drug-use behaviors and should be scaled up further so as to shorten the duration of drug use, thereby reducing HCV infection.
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###### 

Characteristics of the studies.

  Reference Number             Author                      Year of Publication   Regions                      Type of Drug Use              Participants Category (Case/Control)                Sample Size (Case/Control)   Male/Female    Age (Years) \*
  ---------------------------- --------------------------- --------------------- ---------------------------- ----------------------------- --------------------------------------------------- ---------------------------- -------------- ------------------
  \[[@B38-ijerph-16-02345]\]   Chen Hua                    2018                  Sichuan, Mianyang            injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   1829; 977                    2016; 790      39.0 ± 7. 5
  \[[@B39-ijerph-16-02345]\]   Wu Zhen Xiang               2018                  Shanghai, Baoshan            injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   1199; 1604                   2138; 665      39.7 ± 9.86
  \[[@B40-ijerph-16-02345]\]   Jin Jie                     2018                  Zhejiang, Hangzhou           injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   923; 3144                    3329; 638      36.33 ± 8.98
  \[[@B41-ijerph-16-02345]\]   Xu Wen Xin                  2017                  Zhejiang, Jiaxing            injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   51; 398                      356; 93        27.50 ± 12.28
  \[[@B42-ijerph-16-02345]\]   Ye.y                        2016                  Xinjiang, Wulumuji           injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   745; 979                     1 679; 49      35--45
  \[[@B35-ijerph-16-02345]\]   Yun Chang Yan               2016                  Yunnan, Haike                injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   823; 786                     \-             33.8 ± 4.8
  \[[@B43-ijerph-16-02345]\]   Li Ze                       2016                  Yunnan, Dali                 injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   196; 227                     400; 23        15--62
  \[[@B44-ijerph-16-02345]\]   Tao Yi Xin                  2018                  Qinghai, Xining              injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   207; 456                     401; 262       \>20
  \[[@B45-ijerph-16-02345]\]   Zhang Tao                   2012                  Zhejiang, Jinhua             injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   145; 255                     331; 69        31.61 ± 6.80
  \[[@B46-ijerph-16-02345]\]   Shen Han Ding               2011                  Yunnan, Jinning              injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   273; 48                      290; 31        20--78
  \[[@B47-ijerph-16-02345]\]   Liu Qun                     2011                  Hubei, Wuhan                 injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   1156; 184                    1000; 340      32.5 ± 6.2
  \[[@B30-ijerph-16-02345]\]   Bruno Galperim              2004                  Porto Alegre, RS, Brazil     injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   15; 45                       50; 10         31 ± 7
  \[[@B31-ijerph-16-02345]\]   Lisa Maher                  2006                  Sydney, Australia            injecting only                HCV-infected drug uses/non-HCV-infected drug uses   68; 300                      140; 228       \>15
  \[[@B48-ijerph-16-02345]\]   Aldemir B. Oliveira-Filho   2014                  Pará, Brazil                 non-injecting                 HCV-infected drug uses/non-HCV-infected drug uses   106; 194                     191; 109       32.5 ± 10.3
  \[[@B49-ijerph-16-02345]\]   Wei Xiaoli                  2014                  Shanxi, Xian                 injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   5940; 4303                   8653; 1590     37.4 ± 6.7
  \[[@B50-ijerph-16-02345]\]   M. Zeremski                 2012                  New York, USA                non-injecting                 HCV-infected drug uses/non-HCV-infected drug uses   11; 46                       48; 9          44 ± 7
  \[[@B51-ijerph-16-02345]\]   Larry Keen II               2014                  Florida, USA                 injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   274; 208                     284; 198       32.66 ± 7.01
  \[[@B52-ijerph-16-02345]\]   Jenny Iversen               2010                  New South Wales, Australia   injecting only                HCV-infected drug uses/non-HCV-infected drug uses   8100; 7483                   10162; 5421    31 ± 8.8
  \[[@B53-ijerph-16-02345]\]   Victoria L. Demetriou       2010                  Nicosia, Cyprus              injecting only                HCV-infected drug uses/non-HCV-infected drug uses   19; 22                       35; 6          27 (25--31)
  \[[@B27-ijerph-16-02345]\]   Fill MA                     2018                  Tennessee, USA               injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   571; 821                     66:100         \>18
  \[[@B28-ijerph-16-02345]\]   D. N. Aisyah                2017                  London, UK                   injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   119; 422                     1093; 110      \>18
  \[[@B29-ijerph-16-02345]\]   Lillebil Norden             2005                  Huddinge, Sweden             injecting only                HCV-infected drug uses/non-HCV-infected drug uses   37; 5                        28; 14         \-
  \[[@B74-ijerph-16-02345]\]   Huang Dong Sheng            2013                  Yunnan, Baoshan              injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   404; 498                     874; 28        \-
  \[[@B75-ijerph-16-02345]\]   Zhao Hong                   2012                  Neimenggu, Wuhai             injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   580; 331                     856; 55        18--63
  \[[@B35-ijerph-16-02345]\]   Cui Xiu Ling                2005                  Shanxi, Baoji                injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   23; 460                      427; 56        19--52
  \[[@B76-ijerph-16-02345]\]   Shi Wen Ya                  2012                  Beijing, Fengtai             injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   347; 906                     954; 299       \-
  \[[@B77-ijerph-16-02345]\]   Zhong Hai Rong              2010                  Jiangxi, Ganzhou             injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   106; 190                     237; 59        16--51
  \[[@B32-ijerph-16-02345]\]   Wei Da Yin                  2005                  Sichuan, Liangshan           injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   346; 273                     519; 100       28.9 ± 6.4
  \[[@B33-ijerph-16-02345]\]   Sun Yan                     2007                  Hunan, Changsha              injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   662; 110                     452; 320       15--53
  \[[@B54-ijerph-16-02345]\]   Shi Ping                    2009                  Jiangsu, Nanjing             injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   957; 1854                    2305; 506      18--74
  \[[@B55-ijerph-16-02345]\]   Fan Lin Jun                 2010                  Guangxi, Pingnan             injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   203; 47                      245; 5         37 (15--68)
  \[[@B56-ijerph-16-02345]\]   Tang Xue Qin                2011                  Jiangxi, Nanchang            injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   233; 567                     768; 32        18--77
  \[[@B57-ijerph-16-02345]\]   Liu Hui Bin                 2010                  Shanxi, Yulin                injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   352; 125                     440; 37        20--52
  \[[@B58-ijerph-16-02345]\]   Li Guang Qing               2009                  Hunan, Bingzhou              injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   184; 65                      185; 64        32.32 (17--54)
  \[[@B59-ijerph-16-02345]\]   Huang Dao Ping              2017                  Hunan, Changde               injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   1098; 902                    1868; 132      33 (16--63)
  \[[@B60-ijerph-16-02345]\]   Yang Kai                    2018                  Hubei, Yichang               injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   1523; 288                    1411; 400      44.78 ± 6.91
  \[[@B61-ijerph-16-02345]\]   Chen Liang                  2018                  Fujian, Fuqing               injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   3124; 4392                   6630; 886      35.37 ± 8.97
  \[[@B62-ijerph-16-02345]\]   Tang Ren Hai                2018                  Yunnan, Dehong               injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   1369; 6161                   7176; 354      35.14 ± 10.9
  \[[@B63-ijerph-16-02345]\]   Guo Yan                     2017                  Tianjiin, China              injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   1039; 961                    1642; 358      33 (34.5 ± 8.69)
  \[[@B64-ijerph-16-02345]\]   Li Nin                      2016                  Henan, China                 injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   760; 13,195                  11,224; 2724   37.32 ± 8.43
  \[[@B65-ijerph-16-02345]\]   Huang Xi Ming               2016                  Guangdong, China             injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   24,877; 21,652               43,108; 3421   \-
  \[[@B66-ijerph-16-02345]\]   Yao Zhong Zheng             2015                  Xinjiang, Wushi              injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   132; 182                     229; 15        19--69
  \[[@B67-ijerph-16-02345]\]   Wei Li                      2015                  Guangxi, Liuzhou             injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   276; 124                     296; 104       \-
  \[[@B68-ijerph-16-02345]\]   Jin Hui Ya                  2015                  Gansu, Lanzhou               injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   41; 189                      120; 110       39.7--9.1
  \[[@B69-ijerph-16-02345]\]   Ma Ji Xiong                 2014                  Gansu, Baiying               injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   82; 506                      548; 40        30.06 ± 6.3
  \[[@B70-ijerph-16-02345]\]   Pu Li Fang                  2015                  Yunnan, Kaiyuan              injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   239; 36                      209; 66        41.6 ± 6.0
  \[[@B71-ijerph-16-02345]\]   Li Feng                     2015                  Beeijing, Changping          injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   139; 472                     504; 107       \>20
  \[[@B72-ijerph-16-02345]\]   Han Xia                     2014                  Neimenggu, Huhehaote         injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   52; 191                      243; 0         \>20
  \[[@B73-ijerph-16-02345]\]   Feng Yan Jie                2014                  Hebei, Qinhuangdao           injecting and non-injecting   HCV-infected drug uses/non-HCV-infected drug uses   332; 304                     577; 59        \>20

Note: \*: mean ± standard deviation; mean (minimum--maximum); minimum--maximum; mean.
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###### 

The subgroup characteristics of the study factors associated with HCV infection among drug users after omitting the studies with the maximum weight value for the ORs in the subgroup analysis and the results of Egger's test.

  Subgroup Analyses by Study Factors (1) \*      Pooled OR with 95% CI before Reference Omitted (2)   Pooled OR with 95% CI after Reference Omitted (3)   Qualitative Comparison: Reversal of Pooled OR with 95% CI ((2) and (3) Compared)   Quantitative Comparison: Similar Values of Pooled OR with 95% CI ((2) and (3) Compared)   Reference Omitted                                                          Egger's Test   
  ---------------------------------------------- ---------------------------------------------------- --------------------------------------------------- ---------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- -------------------------------------------------------------------------- -------------- -------
  Education level ≤9 years                       1.05 (0.92, 1.21)                                    1.05 (0.91, 1.21)                                   No                                                                                 Yes                                                                                       \[[@B49-ijerph-16-02345]\]                                                 −0.77          0.450
  Sexual behavior without a condom               1.72 (1.07, 2.78)                                    1.50 (1.10, 2.03)                                   No                                                                                 Yes                                                                                       \[[@B65-ijerph-16-02345]\]                                                 −1.79          0.097
  Sharing needles and syringes                   2.244 (1.78, 2.83)                                   2.31 (1.66, 3.23)                                   No                                                                                 Yes                                                                                       \[[@B65-ijerph-16-02345],[@B67-ijerph-16-02345]\]                          0.86           0.395
  Han ethnic group                               0.94 (0.73, 1.20)                                    0.96 (0.70, 1.30)                                   No                                                                                 Yes                                                                                       \[[@B62-ijerph-16-02345]\]                                                 0.27           0.788
  Married or cohabiting with a regular partner   0.88 (0.79, 0.98)                                    0.87 (0.78, 0.97)                                   No                                                                                 Yes                                                                                       \[[@B65-ijerph-16-02345]\]                                                 −1.53          0.139
  Sex (male)                                     1.04 (0.91, 1.18)                                    1.02 (0.90, 1.15)                                   No                                                                                 Yes                                                                                       \[[@B52-ijerph-16-02345],[@B65-ijerph-16-02345]\]                          −1.01          0.319
  Commercial sexual behavior                     1.00 (0.73, 1.38)                                    0.95 (0.61, 1.47)                                   No                                                                                 Yes                                                                                       \[[@B39-ijerph-16-02345],[@B40-ijerph-16-02345],[@B64-ijerph-16-02345]\]   −0.79          0.446
  Unemployment                                   1.50 (1.22, 1.85)                                    1.48 (1.07, 2.06)                                   No                                                                                 Yes                                                                                       \[[@B49-ijerph-16-02345]\]                                                 −0.23          0.831
  Duration of drug use \>5 years                 3.49 (3.24, 3.75)                                    3.47 (3.22, 3.74)                                   No                                                                                 Yes                                                                                       \[[@B58-ijerph-16-02345]\]                                                 −1.78          0.106
  Injecting drug use                             10.11 (8.54, 11.97)                                  10.21 (8.03, 12.97)                                 No                                                                                 Yes                                                                                       \[[@B49-ijerph-16-02345],[@B61-ijerph-16-02345],[@B65-ijerph-16-02345]\]   −0.35          0.731

Note: \*: (1)---means Subgroup Analyses by Study Factors; (2)---means Pooled OR with 95% CI before Reference Omitted; (3)---means Pooled OR with 95% CI after Reference Omitted.

[^1]: These authors contributed equally to the work.
